Archives of Dermatological Research

, Volume 304, Issue 1, pp 7–13 | Cite as

Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic

  • Nicole F. Velez
  • Erin X. Wei-Passanese
  • M. Elaine Husni
  • Elinor A. Mody
  • Abrar A. Qureshi
News & Views


Psoriasis and psoriatic arthritis (PsA) are chronic systemic inflammatory disorders with wide spectrums of cutaneous and musculoskeletal presentations. Management of joint disease in this population can be challenging and often requires the expertise of rheumatology in conjunction with dermatology. A multidisciplinary clinic setting may benefit these patients, and in this study we sought to evaluate the experience of such a model. We performed a retrospective chart review of patients evaluated between October 2003 and October 2009 in the Center for Skin and Related Musculoskeletal Diseases (SARM) at Brigham and Women’s Hospital, Boston, MA, USA, where patients are seen by both an attending rheumatologist and dermatologist. Main outcomes included the presence of comorbidities, accuracy of the initial diagnosis, and escalation of treatment modalities. Over the 6-year period, 510 patients were evaluated. Two hundred sixty-eight patients had psoriasis and/or PsA. The prevalence of comorbidities was high (45% hypertension, 46% hyperlipidemia, 19% diabetes, and 36% history of the past or current smoking). Visit in SARM resulted in a revised diagnosis that differed from the previous diagnosis at outside clinics in 46% of cases. Patients were more likely to receive a systemic medication after the evaluation in SARM as compared to before, 25 versus 15%, respectively, with an odds ratio of 5.1. Patients were also more likely to be treated with a biologic agent after the evaluation in SARM as compared to before, 37 versus 16%, respectively. Multidisciplinary care may facilitate the diagnosis of joint disease and offers a more comprehensive treatment approach for patients with both psoriasis and PsA. Our data can be used to support the efforts to provide integrated rheumatologic and dermatologic care for this population.


  1. 1.
    Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P et al (2006) Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology 45(8):1029–1038PubMedCrossRefGoogle Scholar
  2. 2.
    Barra L, Pope JE, Payne M (2009) Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 36(7):1421–1428PubMedCrossRefGoogle Scholar
  3. 3.
    Berthelot JM, Klarlund M, McGonagle D, Bernelot-Moens HJ, Calin A, Harrison B et al (2001) Lessons from an international survey of paper cases of 10 real patients from an early arthritis clinic. CRI (Club Rhumatismes et Inflammation) Group. J Rheumatol 28(5):975–981PubMedGoogle Scholar
  4. 4.
    Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S et al (2011) Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 303(6):381–388PubMedCrossRefGoogle Scholar
  5. 5.
    Chandran V, Schentag CT, Gladman DD (2008) Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol 35(10):2069–2070PubMedGoogle Scholar
  6. 6.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572PubMedCrossRefGoogle Scholar
  7. 7.
    Curtis JR, Arora T, Narongroeknawin P, Taylor A, Bingham CO, Cush J et al (2010) The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther 12(4):R144PubMedCrossRefGoogle Scholar
  8. 8.
    Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 285(19):2486–2497CrossRefGoogle Scholar
  9. 9.
    Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F et al (2008) The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 59(5):772–780PubMedCrossRefGoogle Scholar
  10. 10.
    Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ (2004) Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 51(5):704–708PubMedCrossRefGoogle Scholar
  11. 11.
    Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T et al (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53(4):573PubMedCrossRefGoogle Scholar
  12. 12.
    Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296(14):1735–1741PubMedCrossRefGoogle Scholar
  13. 13.
    Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41(6):1103–1110PubMedCrossRefGoogle Scholar
  14. 14.
    Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML (1990) Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 17(6):809–812PubMedGoogle Scholar
  15. 15.
    Gottlieb AB, Dann F (2009) Comorbidities in patients with psoriasis. Am J Med 122(12):1150 e1151–e1159Google Scholar
  16. 16.
    Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M (2007) Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 57(6):963–971PubMedCrossRefGoogle Scholar
  17. 17.
    Ibrahim G, Waxman R, Helliwell PS (2009) The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61(10):1373–1378PubMedCrossRefGoogle Scholar
  18. 18.
    Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42(12):1460–1468PubMedCrossRefGoogle Scholar
  19. 19.
    Kavanaugh A, Antoni CE, Krueger GG, Yan S, Bala M, Dooley LT et al (2006) Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65(4):471–477PubMedCrossRefGoogle Scholar
  20. 20.
    Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A et al (2006) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65(8):1038–1043PubMedCrossRefGoogle Scholar
  21. 21.
    Kavanaugh AF, Ritchlin CT (2006) Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33(7):1417–1421PubMedGoogle Scholar
  22. 22.
    Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR et al (2011) Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 25(2):157–163PubMedCrossRefGoogle Scholar
  23. 23.
    Kurd SK, Gelfand JM (2009) The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 60(2):218–224PubMedCrossRefGoogle Scholar
  24. 24.
    Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM (2010) The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 146(8):891–895PubMedCrossRefGoogle Scholar
  25. 25.
    McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42(6):778–783PubMedCrossRefGoogle Scholar
  26. 26.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289PubMedCrossRefGoogle Scholar
  27. 27.
    Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272PubMedCrossRefGoogle Scholar
  28. 28.
    Mody E, Husni ME, Schur P, Qureshi AA (2007) Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. Br J Dermatol 157(5):1050–1051PubMedCrossRefGoogle Scholar
  29. 29.
    Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M et al (2007) German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 299(3):111–138PubMedCrossRefGoogle Scholar
  30. 30.
    Onel KB, Onel K (2010) Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res 62(7):1024–1028CrossRefGoogle Scholar
  31. 31.
    Palazzi C, Olivieri I, Petricca A, Salvarani C (2002) Rheumatoid arthritis or psoriatic symmetric polyarthritis? A difficult differential diagnosis. Clin Exp Rheumatol 20(1):3–4PubMedGoogle Scholar
  32. 32.
    Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145(6):700–703PubMedCrossRefGoogle Scholar
  33. 33.
    Regier DA, Bansback N, Dar Santos A, Marra CA (2007) Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev Pharmacoecon Outcome Res 7(2):155–169CrossRefGoogle Scholar
  34. 34.
    Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL (2010) Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res 62(3):345–353CrossRefGoogle Scholar
  35. 35.
    Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M et al (2003) Clinical and genetic aspects of psoriatic arthritis “sine psoriasis”. J Rheumatol 30(12):2638–2640PubMedGoogle Scholar
  36. 36.
    Shang Q, Tam LS, Yip GW, Sanderson JE, Zhang Q, Li EK et al (2011) High prevalence of subclinical left ventricular dysfunction in patients with psoriatic arthritis. J Rheumatol 38(7):1363–1370PubMedCrossRefGoogle Scholar
  37. 37.
    Solomon DH, Love TJ, Canning C, Schneeweiss S (2010) Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 69(12):2114–2117PubMedCrossRefGoogle Scholar
  38. 38.
    Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG (2010) Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 146(7):721–726PubMedCrossRefGoogle Scholar
  39. 39.
    Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9(2):136–139PubMedCrossRefGoogle Scholar
  40. 40.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673PubMedCrossRefGoogle Scholar
  41. 41.
    Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 61(2):233–239PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Nicole F. Velez
    • 1
  • Erin X. Wei-Passanese
    • 2
  • M. Elaine Husni
    • 3
  • Elinor A. Mody
    • 4
  • Abrar A. Qureshi
    • 1
  1. 1.Department of DermatologyBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Department of Rheumatic and Immunologic DiseasesCleveland ClinicClevelandUSA
  4. 4.Division of Allergy, Immunology and Rheumatology, Department of MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations